Citations

Clear

56 citation(s) found for "Lee, Nancy".

The expression of the abundant secondary granule proteins MBP-1 and EPO is required for the maturation of eosinophil-lineage committed progenitor cells in the hematopoietic compartments of mice (153.27)
Doyle, Alfred D. , Ochkur, Sergei I. , McGarry, Michael P. , Nguyen, David T. , Protheroe, Cheryl, Colbert, Dana, Dyer, Kimberly D., Rosenberg, Helene F. , Lee, Nancy, Jacobsen, Elizabeth A. , Shim, Kevin G. , Lee, James S.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 186 | Issue: 1_Supplement | Pages: 153.27-153.27

10.4049/jimmunol.186.supp.153.27 Get It

Abstract Eosinophil effector functions have been hypothesized to be mediated in part by the release of proteins stored in the secondary granules of mature cells of this leukocyte lineage. Major basic protein-1 (MBP-1) and eosinophil peroxidase (EPO) comprise the majority of protein in these granules. No role has been speculated for these proteins in eosinophilopoiesis and/or the accumulation of mature cells in circulation. Methods: Eosinophilopoiesis and eosinophil accumulation in the periphery were assessed in single and double knockout (MBP-1-/- and/or EPO-/-) mice. Bone marrow and peripheral blood leukocytes were assessed by IHC, FACS and in vitro cell culture assays. Mice were subjected to an acute OVA protocol assessing induced pulmonary pathologies in each of the strains of granule protein knockout mice. Results: We demonstrate that, unlike the single deficiency of MBP-1 or EPO, the absence of both granule proteins resulted in the loss of peripheral blood eosinophils. IHC assessments of bone marrow and spleen demonstrate that eosinophil lineage commitment occurs in these mice. However, these assessments and FACS studies demonstrated a blockade in the maturation of eosinophil-lineage committed cells. This blockade is not rescued by ex vivo culture or by bone marrow engraftment into wild type recipient mice. Similar to other eosinophil-less mouse models, MBP-1-/-/EPO-/- mice also fail to develop pulmonary inflammation in an OVA protocol.
Eosinophils regulate dendritic cell-induced Th2 polarization following allergen challenge in a mouse model of asthma (151.10)
Zellner, Katie R. , Colbert, Dana, Lee, Nancy, Jacobsen, Elizabeth A. , Lee, James

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 186 | Issue: 1_Supplement | Pages: 151.10-151.10

10.4049/jimmunol.186.supp.151.10 Get It

Abstract Eosinophil recruitment and accumulation in the lungs of asthmatics is a hallmark feature of asthma. The causative relationship between eosinophils and induced Th2 pulmonary pathologies remains unclear. Our data suggest a novel role for eosinophils as immune modulators that drive Th2-mediated pulmonary pathologies through modulation of dendritic cell function leading to the suppression of Th1/Th17 immune responses. Methods: Eosinophils and ovalbumin (OVA)-pulsed myeloid dendritic cells were adoptively transferred into IL-5-/- (eosinophil-low) or PHIL mice (eosinophil-null) at the time of allergen challenge using an established acute OVA protocol. Allergen-induced pulmonary changes were assessed as changes in lung and lung draining lymph node (LDLN) cells, activation/polarization of T cells, and induced lung histopathologies. Conclusions: We demonstrate that a threshold level of eosinophils must migrate to the lung draining lymph node to promote dendritic cell recruitment and thus activation of antigen-specific memory T cells. Expression of MHC II or CCR7 on eosinophils is not necessary for proliferation of T cells in the LDLN. These lymphatic eosinophils are necessary to suppress Th1/Th17 neutrophilic polarized immune responses initiated by OVA-pulsed dendritic cells during allergen challenge. These results imply an important function for eosinophils in modulating the balance between Th2 and Th1/Th17 pathways in the development of allergic respiratory inflammation.
In vitroassessment of chemokine receptor-ligand interactions mediating mouse eosinophil migration
Borchers, Michael T. , Ansay, Tracy, DeSalle, Rob , Daugherty, Bruce L. , Shen, Huahao , Lee, Nancy A., Lee, James J. , Metzger, Michael J.

Mayo Clinic

Journal of Leukocyte Biology | September 28, 2022 | Volume: 71 | Issue: 6 | Pages: 1033-1041

10.1189/jlb.71.6.1033 Get It

AbstractEosinophil migration from circulation is controlled, in part, by chemokines through a family of G-protein-coupled chemokine receptors (CCR). Studies of human eosinophils have demonstrated that signaling through CCR3 receptors is a prominent pathway leading to chemotaxis, although several other receptor-ligand interactions also appear to mediate eosinophil recruitment. The availability of genetically unique strains of mice permits a reductionist approach to assess the signaling pathways in experimental models of human disease. However, despite similarities in these pathways between mice and humans, significant species differences exist, complicating the translation of results from animal models to humans. Purified mouse eosinophils were used in this study to investigate the chemokine receptor expression and the activities of 18 chemokines. Mouse eosinophils isolated from IL-5 transgenic mice expressed transcripts encoding the chemokine receptors CCR1, CCR2, CCR3, CCR5, CCR8, CXCR2, and CXCR4, but not CCR4. Mouse eosinophils also migrated in response to human and mouse eotaxin-1 and -2, but not human eotaxin-3. In addition, the induced migration of mouse eosinophils by TARC, MIP-1β, and KC suggests that unidentified receptor-ligand interactions contribute to eosinophil recruitment. It is interesting that the potent chemoattractant of human eosinophils, RANTES, was unable to mediate mouse eosinophil migration. Furthermore, despite the ability of MIP-1α to bind receptors on purified mouse eosinophils, it was only able to induce significant eosinophil migration in a mixed splenocyte population and was unable to induce migration of highly purified eosinophils. Collectively, these observations reveal physiologically relevant distinctions in mechanisms mediating human and mouse eosinophil migration that potentially reflect evolutionary disparities between these species.
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial
Sherman, Eric J. , Pei, Xin , Grkovski, Milan , Paudyal, Ramesh , Katabi, Nora , Yamaguchi, Takafumi N. , Daniel, J. , Lee, Simon , Shah, Rachna , Ratnakumar, Abhirami , Salcedo, Adriana , Tsai, C. Jillian , McBride, Sean M. , Boyle, Jay, Singh, Bhuvanesh , Damerla, Rama Rao , Paula, Arnaud Da Cruz , Price, Katharine A. , Moore, Eric J. , García, Joaquín J. , Foote, Robert L. , Humm, John L. , Shukla‐Dave, Amita , Pfister, David G. , Lee, Nancy Y. , Pei, Xin , Grkovski, Milan , Paudyal, Ramesh , Yamaguchi, Takafumi N , Ma, Daniel , Shah, Rachna , Kumar, Rahul , Kuo, Fengshen , Ratnakumar, Abhirami , Tsai, Chiaojung J , Morris, Luc G T , Higginson, Daniel S , Price, Katharine, Moore, Eric J , Foote, Robert , Boutros, Paul C , Shukla-Dave, Amita , Riaz, Nadeem , Schöder, Heiko , Selenica, Pier , Kumar, Rahul , Kuo, Fengshen , Aleynick, Nathan , Brown, David N. , Zhang, Zhigang , Hatzoglou, Vaios , Liu, Lydia , Higginson, Daniel S. , Ho, Alan L. , Wong, Richard J. , Chan, Timothy An-thy , Powell, Simon N. , Boutros, Paul C. , Reis‐Filho, Jorge S. , Tsai, CJillian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 11, 2020 | Volume: 113 | Issue: 6 | Pages: 742-751

10.1093/jnci/djaa184 | PMID 33429428 Get It

Abstract Background Patients with human papillomavirus–related oropharyngeal cancers have excellent outcomes but experience clinically significant toxicities when treated with standard chemoradiotherapy (70 Gy). We hypothesized that functional imaging could identify patients who could be safely deescalated to 30 Gy of radiotherapy. Methods In 19 patients, pre- and intratreatment dynamic fluorine-18-labeled fluoromisonidazole positron emission tomography (PET) was used to assess tumor hypoxia. Patients without hypoxia at baseline or intratreatment received 30 Gy; patients with persistent hypoxia received 70 Gy. Neck dissection was performed at 4 months in deescalated patients to assess pathologic response. Magnetic resonance imaging (weekly), circulating plasma cell-free DNA, RNA-sequencing, and whole-genome sequencing (WGS) were performed to identify potential molecular determinants of response. Samples from an independent prospective study were obtained to reproduce molecular findings. All statistical tests were 2-sided. Results Fifteen of 19 patients had no hypoxia on baseline PET or resolution on intratreatment PET and were deescalated to 30 Gy. Of these 15 patients, 11 had a pathologic complete response. Two-year locoregional control and overall survival were 94.4% (95% confidence interval = 84.4% to 100%) and 94.7% (95% confidence interval = 85.2% to 100%), respectively. No acute grade 3 radiation–related toxicities were observed. Microenvironmental features on serial imaging correlated better with pathologic response than tumor burden metrics or circulating plasma cell-free DNA. A WGS-based DNA repair defect was associated with response (P = .02) and was reproduced in an independent cohort (P = .03). Conclusions Deescalation of radiotherapy to 30 Gy on the basis of intratreatment hypoxia imaging was feasible, safe, and associated with minimal toxicity. A DNA repair defect identified by WGS was predictive of response. Intratherapy personalization of chemoradiotherapy may facilitate marked deescalation of radiotherapy.
Management of primary skin cancer during a pandemic: Multidisciplinary recommendations
Baumann, Brian C. , MacArthur, Kelly M. , Brewer, Jerry D., Barker, Christopher A. , Etzkorn, Jeremy R. , Jellinek, Nathaniel J., Scott, Jeffrey F. , Baumann, John C., Manian, Farrin A. , Devlin, Phillip M. , Michalski, Jeff M. , Lee, Nancy Y. , Wilson, Lynn D., Miller, Christopher J. , Mendenhall, William M , Baumann, Brian C , Gay, Hiram A. , Thorstad, Wade , Perez, Carlos A. , Miller, Christopher J.

Mayo Clinic

Cancer | June 1, 2020 | Volume: 126 | Issue: 17 | Pages: 3900-3906

10.1002/cncr.32969 | PMID 32478867 Get It

During the coronavirus disease 2019 (COVID‐19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID‐19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID‐19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID‐19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early‐stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID‐19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors ≥T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors ≥T2b should be prioritized, but a 1‐month to 2‐month delay is unlikely to worsen disease‐specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.
Cloning of the murine eosinophil peroxidase gene (mEPO): characterization of a conserved subgroup of mammalian hematopoietic peroxidases
Horton, Margaret A., Larson, Kirsten A., Lee, Nancy A., Lee, James J.

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 60 | Issue: 2 | Pages: 285-294

10.1002/jlb.60.2.285 | PMID 8773591 Get It

Abstract The mouse eosinophil peroxidase (mEPO) gene was cloned by screening a random-primed bone marrow cDNA library at reduced criteria using a hEPO cDNA. An mEPO cDNA was subsequently used to isolate the mEPO gene from a λ-genomic library. The mEPO gene displays a high degree of conservation with its human homologue: the transcription units are approximately the same size, conserve the relative size and position of the 12 exons associated with each gene, and at a nucleotide level the mouse and human EPO genes are 86% identical in the protein coding regions and 66% identical in the 3'-untranslated trailer regions. This strong conservation extends to the encoded proteins which show ~90% amino acid identity. Expression of the mEPO gene is restricted to tissues containing eosinophil progenitor cells (e.g., bone marrow and spleen), a pattern similar to the expression of another murine eosinophil granule protein, major basic protein.
Identification of a new murine eosinophil major basic protein (mMBP) gene: cloning and characterization of mMBP-2
Macias, MiMi P. , Denzler, Karen L., Larson, Kirsten A., Lee, Nancy A., Welch, Kenneth C. , Lee, James J.

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 67 | Issue: 4 | Pages: 567-576

10.1002/jlb.67.4.567 | PMID 10770291 Get It

Abstract We have identified a new eosinophil major basic protein gene family member in the mouse and have given it the designation murine major basic protein-2 (mMBP-2). The gene was initially characterized as a unique expressed sequence tag (EST) clone having significant identity to the previously recognized member of this gene family, mMBP-1. The EST was used to screen and isolate mMBP-2 from a bone marrow cDNA library. In addition, a genomic clone of mMBP-2 was isolated and this gene was shown to be physically linked to within 100 kb of mMBP-1 on the central region of mouse chromosome 2. Progressive similarity alignment of the deduced mMBP-2 open reading frame demonstrates the apparent conservation of the “pre-pro-mature” protein structure found in the other known mammalian MBPs. Mature mMBP-2 maintains the cationic nature associated with these proteins with a predicted pI of 9.95. However, unlike the human MBPs, which display a three orders of magnitude charge difference [hMBP-1 (pI11.4) vs. hMBP-2 (pI8.7)], mMBP-2 is only slightly less cationic than mMBP-1 (pI 10.5). Expression studies demonstrate that transcription of the mMBP-2 gene parallels mMBP-1 and is confined to hematopoietic compartments engaged in eosinophilopoiesis. Moreover, using mMBP-1 knockout mice and immunohistochemistry with an antisera that recognizes both mMBP-1 and -2, we demonstrate that mMBP-2 protein expression is restricted to eosinophil lineage-committed cells. J. Leukoc. Biol. 67: 567–576; 2000.
Frontline Science: Eosinophil-deficient MBP-1 and EPX double-knockout mice link pulmonary remodeling and airway dysfunction with type 2 inflammation
Ochkur, Sergei I. , Doyle, Alfred D. , Jacobsen, Elizabeth A. , LeSuer, William E., Li, Wen , Protheroe, Cheryl, Zellner, Katie R. , Colbert, Dana, Shen, Hua-Hao, Irvin, C. G., Lee, James J. , Lee, Nancy A., Protheroe, Cheryl A, Jacobsen, Elizabeth A

Mayo Clinic

Journal of Leukocyte Biology | May 18, 2017 | Volume: 102 | Issue: 3 | Pages: 589-599

10.1189/jlb.3hi1116-488rr | PMID 28515227 Get It

Abstract Eosinophils and the release of cationic granule proteins have long been implicated in the development of the type 2–induced pathologies linked with respiratory inflammation. Paradoxically, the ablation of the two genes encoding the most abundant of these granule proteins, major basic protein-1 (MBP-1) and eosinophil peroxidase (EPX), results in a near collapse of eosinophilopoiesis. The specificity of this lineage ablation and the magnitude of the induced eosinopenia provide a unique opportunity to clarify the importance of eosinophils in acute and chronic inflammatory settings, as well as to identify potential mechanism(s) of action linked with pulmonary eosinophils in those settings. Specifically, we examined these issues by assessing the induced immune responses and pathologies occurring in MBP-1−/−/EPX−/− mice after 1) ovalbumin sensitization/provocation in an acute allergen-challenge protocol, and 2) crossing MBP-1−/−/EPX−/− mice with a double-transgenic model of chronic type 2 inflammation (i.e., I5/hE2). Acute allergen challenge and constitutive cytokine/chemokine expression each induced the accumulation of pulmonary eosinophils in wild-type controls that was abolished in the absence of MBP-1 and EPX (i.e., MBP-1−/−/EPX−/− mice). The expression of MBP-1 and EPX was also required for induced lung expression of IL-4/IL-13 in each setting and, in turn, the induced pulmonary remodeling events and lung dysfunction. In summary, MBP-1−/−/EPX−/− mice provide yet another definitive example of the immunoregulatory role of pulmonary eosinophils. These results highlight the utility of this unique strain of eosinophil-deficient mice as part of in vivo model studies investigating the roles of eosinophils in health and disease settings.
Lung Pathologies in a Chronic Inflammation Mouse Model Are Independent of Eosinophil Degranulation
Jacobsen, Elizabeth A. , Ochkur, Sergei I. , Doyle, Alfred D. , LeSuer, William E., Li, Wen , Protheroe, Cheryl, Colbert, Dana, Zellner, Katie R. , Shen, Huahao , Irvin, Charles G. , Lee, James J. , Lee, Nancy A., Protheroe, Cheryl A, Jacobsen, Elizabeth A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 6, 2017 | Volume: 195 | Issue: 10 | Pages: 1321-1332

10.1164/rccm.201606-1129oc | PMID 27922744 Get It

Abstract Rationale The release of eosinophil granule proteins in the lungs of patients with asthma has been dogmatically linked with lung remodeling and airway hyperresponsiveness. However, the demonstrated inability of established mouse models to display the eosinophil degranulation occurring in human subjects has prevented a definitive in vivo test of this hypothesis. Objectives To demonstrate in vivo causative links between induced pulmonary histopathologies/lung dysfunction and eosinophil degranulation. Methods A transgenic mouse model of chronic T-helper cell type 2–driven inflammation overexpressing IL-5 from T cells and human eotaxin 2 in the lung (I5/hE2) was used to test the hypothesis that chronic histopathologies and the development of airway hyperresponsiveness occur as a consequence of extensive eosinophil degranulation in the lung parenchyma. Measurement and Main Results Studies targeting specific inflammatory pathways in I5/hE2 mice surprisingly showed that eosinophil-dependent immunoregulative events and not the release of individual secondary granule proteins are the central contributors to T-helper cell type 2–induced pulmonary remodeling and lung dysfunction. Specifically, our studies highlighted a significant role for eosinophil-dependent IL-13 expression. In contrast, extensive degranulation leading to the release of major basic protein-1 or eosinophil peroxidase was not causatively linked to many of the induced pulmonary histopathologies. However, these studies did define a previously unappreciated link between the release of eosinophil peroxidase (but not major basic protein-1) and observed levels of induced airway mucin. Conclusions These data suggest that improvements observed in patients with asthma responding to therapeutic strategies ablating eosinophils may occur as a consequence of targeting immunoregulatory mechanisms and not by simply eliminating the destructive activities of these purportedly end-stage effector cells.
Bladder cancer: Predicting response to BCG.
Núñez-Nateras, Rafael , Stanton, Melissa, Ferrigni, Erin , Protheroe, Cheryl, Lee, Nancy A., Lee, James J. , Castle, Erik P.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 6_suppl | Pages: 287-287

10.1200/jco.2013.31.6_suppl.287 Get It

287 Background: Our preliminary immunohistochemical studies of bladder cancer patients have shown that the inflammatory/immune responses associated with bladder cancer appear to be Th2-polarized as judged by the preponderance of tumor infiltrating GATA-3+ (Th2) vs. T-bet+ (Th1) T cells, as well as by evidence of tumor-associated eosinophil infiltration and activation. The standard-of-care treatment for Tis bladder cancer is intravesical administration of BCG, a Th1-polarizing immunomodulator. The aim of the present study was to assess the Th2/Th1 ratio correlation with response to BCG therapy in patients with Tis bladder cancer. Methods: Two groups of patients were studied. Group A included 20 patients that responded to BCG, and Group B included 20 patients that did not respond to therapy. Response to BCG was determined as presence/absence of disease at 6 months post-BCG therapy. The initial diagnostic biopsies of these patients were subjected to immunohistochemical analysis using commercially available antibodies specific for Th2 (GATA-3+) and Th1 (T-bet+) lymphocytes, and our unique monoclonal antibody specific for eosinophil peroxidase (EPX-mAb). Ten random high powered (400X) fields at the maximum focus of mononuclear infiltration were examined and the number of GATA 3+ and T-bet+ tumor infiltrating T cells were counted to define the G/T ratio for each patient sample. Eosinophils and their degranulation activity were counted in the same fields. Results: Patients with response to BCG therapy had a G/T ratio of ≥ 3 and patients with non-response to BCG therapy had a G/T ratio of ≤ 1.5. Correlation of these scores with subsequent patient outcomes following BCG immune therapy demonstrated that patient responsiveness (i.e., tumor elimination at 6 months) trended with the higher G/T ratio patients. In addition, initial biopsies of BCG responsive patients display a higher number of eosinophils and degranulation relative to BCG non-responsive patients. Conclusions: Evaluations of initial biopsies revealed a strong correlation between Th1 and Th2 immune response with BCG therapy outcomes. The development of specific and novel tools to identify/measure Th2 immune responses in Tis bladder cancer provides a unique opportunity to predict outcomes at the time of diagnosis.